Evaluating the Next Steps for Research in Myelofibrosis
Laura Michaelis, MD, discusses the next steps for research in the treatment of myelofibrosis following the addition of fedratinib (Inrebic) to the armamentarium of JAK inhibitors.
Related Articles
Case 2—Metastatic NSCLC With a ROS1 Alteration: Presentation and Discussion
Panelists discuss the presentation and management of a case involving metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration, focusing on treatment approaches and…
Bexobrutideg Gains FDA Orphan Drug Status in Waldenström Macroglobulinemia
Bexobrutideg, a first-in-class Bruton’s tyrosine kinase degrader, has been granted orphan drug designation from the FDA in Waldenström macroglobulinemia.
Overall Survival Benefit Update From RATIONALE-305
Panelists discuss how RATIONALE-305 trial data shows promising updated overall survival benefits for patients receiving tislelizumab plus chemotherapy compared to placebo plus chemotherapy in advanced…
Orca-T Improves cGVHD-Free Survival Across Hematologic Malignancies
Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T study.
Jacobs and Peers Consider Third-Line Treatment in Relapsed/Refractory CLL
During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for chronic lymphocytic leukemia.
Clinical Insights and Patient Considerations for Frontline TKI Therapy in Advanced uHCC
An expert discusses how treatment selection for first-line (1L) tyrosine kinase inhibitor (TKI) therapy in advanced hepatocellular carcinoma (HCC) requires careful evaluation of multiple factors,…
Phase 3 Trial of the ArteraAI Prostate Test Begins Enrollment
The first patient has been enrolled in the PROSTATE-IQ trial of ArteraAI, a multimodal artificial intelligence biomarker test.
AE Management With TKIs and Belzutifan
A panelist discusses how managing adverse events associated with TKIs and belzutifan requires a proactive approach encompassing prevention strategies, regular monitoring, dose modifications when needed…
Kato Breaks Down FDA Approval of Tislelizumab in Esophageal Cancer
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.
Case 2—Metastatic NSCLC With a ROS1 Alteration: Presentation and Discussion
Panelists discuss the presentation and management of a case involving metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration, focusing on treatment approaches and…